Vasculitis and anti-thyroid medication

Sofia Lionaki et al. Nephrol Dial Transplant. 2008 May.

. 2008 May;23(5):1766-8; author reply 1768.

doi: 10.1093/ndt/gfm887. Epub 2007 Dec 21.

No abstract available

Conflict of interest statement

Conflict of interest statement. None declared.

Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study.
Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH. Lionaki S, et al. Nephrol Dial Transplant. 2007 Dec;22(12):3508-15. doi: 10.1093/ndt/gfm493. Epub 2007 Aug 8. Nephrol Dial Transplant. 2007. PMID: 17686815

1. Lionaki S, Hogan SL, Falk RJ, et al. Association of thyroid disease and its treatment with the onset of ANCA small-vessel vasculitis. Nephrol Dial Transplant. 2007;22:3508–3515. - PubMed
1. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36:130–147. - PubMed
1. Slot MC, Links TP, Stegeman CA, et al. Occurrence of antineutriphil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arth Rheum. 2005;53:108–113. - PubMed
1. Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves’ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001;54:651–654. - PubMed
1. Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves’ disease treated with propylthiouracil. J Clin Endocrinol Metab. 2000;85:4270–4273. - PubMed